Trattamento dei pazienti affetti da COVID-19 utilizzando cellule staminali gelatinose-mesenchimali di Wharton

Brief Summary:Lo scopo di questo studio è indagare il potenziale utilizzo delle cellule staminali mesenchimali gelatinose di Wharton (WJ-MSC) per il trattamento di pazienti con diagnosi di infezione da Corona Virus SARS-CoV-2, e mostrare sintomi di COVID-19.

Condition or diseaseIntervention/treatmentPhase
Use ofCellule staminali for COVID-19 TreatmentBiological: WJ-MSCPhase 1

Descrizione dettagliata:

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.


NBScienza

organizzazione di ricerca a contratto

terapia con cellule staminali